Tempus AI Inc. stocks have been trading up by 8.06 percent amid strong investor optimism from its latest AI healthcare advances.

Weekly Update Aug 17 – Aug 21, 2026: On Saturday, August 22, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 8.06%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Tempus AI (TEM) sits in a structurally attractive niche at the intersection of diagnostics, real‑world data and AI, but fundamentals remain transitionary. Despite a very strong 73.5% gross margin and Q2 EBITDA of $21.4m, consolidated margins are still deeply negative (EBIT margin –14.4%, profit margin –17.8%), with ROE and ROA sharply negative. Cash burn is manageable given $816m of liquidity and a 3.3x current ratio, but equity is thin ($445m) against a $12.6bn EV and rich 8.4x sales multiple.

Technically, TEM has pivoted into a clear short‑term uptrend: a rapid sequence from 51.18 to 72.02 over five sessions shows aggressive dip‑buying and successful breakouts through prior highs, with intraday 5‑minute candles (and expanding volume) confirming buyers dominating every pullback. The dominant level to trade against is the 65–66 zone, which should now act as primary support; a sustained break below 65 would signal exhaustion, while momentum‑oriented longs can anchor entries above 68 with a first upside target near 78.

More Breaking News

• SPCX Slides As Headline Risk And Competition Hammer Sentiment
• SOFI Stock Slips As Analyst Warns Of $1B Headwind
• WULF Stock Climbs As AI Data-Center Funding Risks Mount
• FDXF Stock Climbs As Price Action Attracts Momentum Traders

Catalysts are strong: Q2 revenue beat, raised FY guidance to ~$1.6bn, margin expansion to mid‑60s and a turn to positive net income meaningfully outpace Healthcare and Healthcare Providers & Services peer medians on growth, albeit with weaker profitability and higher valuation risk. The Personalis MRD acquisition deepens oncology moat despite governance noise; expanded credit facilities and growing data‑licensing scale add strategic flexibility. I expect continued rerating, with a 6–12 month target range of $80–85 and technical support at 65, resistance at 78–80.

Quick Financial Overview

Tempus AI (TEM) is starting to show what operating leverage looks like. Q2 revenue of roughly $1.27B on a trailing basis and guidance raised toward about $1.6B for the year signal a business that is growing into its cost base. A 64% gross margin is strong for any data-heavy healthcare platform and gives room for future reinvestment. Reaching positive net income, even with thin margins, is a key psychological shift for traders who watched the name trade on story only.

At the same time, the key ratios remind us this is still a high-risk growth story. Profit margins on a trailing basis are negative, with EBIT margin at about -14.4% and profit margin near -18%. Return on equity and return on assets are both sharply negative, which is common in early-scale AI and genomics names but still a flag for risk. A price-to-sales multiple around 8.4 and price-to-book over 27 show that Tempus AI Inc. still trades at a premium to book value, supported by its data and software optionality rather than traditional assets.

The balance sheet is reasonably solid for an aggressive grower. Cash and short-term investments above $800M, a current ratio of about 3.3, and total debt-to-equity near 0.61 suggest room to fund R&D and acquisitions like Personalis without immediate strain. Free cash flow is negative, around -$18.6M last quarter, which means the company still leans on capital markets and debt. For traders, the line is simple: the business is moving toward self-funding, but is not there yet.

On the chart, the weekly data show a strong momentum swing. After dipping from $51.66 to a $49.03 close, Tempus AI (TEM) ripped to a $62.10 close, then pushed higher to $66.39 and finally $72.02. That is a quick move of roughly 45% from the recent low to the latest weekly close, confirming that the market is reacting positively to the earnings beat, guidance raise, and Personalis deal story. The intraday snapshot where price surged from the mid-$60s to the low-$70s in a single session backs the idea of a squeeze-style move, likely fueled by shorts covering and momentum traders piling in.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.